Nature de la demande
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
b6sDb21GqAT6WaTn
Écouter
